Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer Charles S. Grob, Alicia L. Danforth, Gurpreet S. Chopra, Marycie Hagerty, Charles R. McKay, Adam L. Halberstadt, George R. Greer Archive of General Psychiatry, 2010, 68, (1), 71–78 doi: 10.1001/archgenpsychiatry.2010.116 Context : Researchers conducted extensive investigations of hallucinogens in the 1950s and 1960s. By the early 1970s, however, political and cultural pressures forced the cessation of all projects. This investigation reexamines a potentially promising clinical application of hallucinogens in the treatment of anxiety reactive to advanced-stage cancer. Objective : To explore the safety and efficacy of psilocybin in patients with advanced-stage cancer and [...]
Lire la suiteMedical Marijuana Use in Oncology : A Review Gianna Wilkie, Bachir Sakr, Tina Rizack JAMA Oncology, 2016, 2, (5), 670-675. doi:10.1001/jamaoncol.2016.0155 IMPORTANCE : Medicinal marijuana use is currently legal in 23 states and the District of Columbia. As more states approve marijuana use for medical indications, physicians will be asked by their patients for more information regarding the risks and benefits of use. This article reviews the history, adverse effects, and proposed mechanisms of action of marijuana and summarizes the available literature regarding symptom relief and therapeutic value in patients with cancer. OBSERVATIONS : Marijuana in oncologymay have potential for use as an antiemetic, for [...]
Lire la suiteMedical Use of Cannabis in 2019 Kevin P. Hill, MD, MHS JAMA, Published online August 9, 2019 doi:10.1001/jama.2019.11868 Nearly 10% of cannabis users in the United States report using it for medicinal purposes.1 As of August 2019, 33 states and the District of Columbia have initiated policies allowing the use of cannabis or cannabinoids for the management of specific medical conditions. Yet, the federal government still classifies cannabis as illegal, complicating its medical use and research into its effectiveness as a treatment for the various conditions purported to benefit from cannabis pharmacotherapy. Because of this conflict and restrictions on cannabis research, evidence of the [...]
Lire la suiteIbogaine : A review - Chapter 1 Kenneth R. Alper The Alkaloids. Chemistry and Biology, 2001, 56, 38 pp DOI: 10.1016/S0099-9598(01)56005-8 I. Introduction, Chemical Properties, and Historical Time Line ..................... A. Introduction................................................................................................... B. Chemical Structure and Properties .............................................................. C. Historical Time Line ..................................................................................... II. Mechanisms of Action .................................................................................. A. Neurotransmitter Activities........................................................................... B. Discrimination Studies.................................................................................. C. Effects on Neuropeptides............................................................................... D. Possible Effects on Neuroadaptations Related to Drug Sensitization or Tolerance ....................................................................................................... III. Evidence of Efficacy in Animal Models........................................................ A. Drug Self-Administration .............................................................................. B. Acute Opioid Withdrawal .............................................................................. C. Conditioned Place Preference........................................................................ D. Locomotor Activity........................................................................................ E. Dopamine Efflux............................................................................................. IV Evidence of Efficacy and Subjective Effects in Humans .............................. A. Evidence of Efficacy........................................................................................ B. Subjective Effects ........................................................................................... V. Pharmacokinetics ........................................................................................... A. Absorption....................................................................................................... B. Distribution .................................................................................................... C. Metabolism .................................................................................................... D. Excretion [...]
Lire la suiteThe Bastiaans Method of Drug-Assisted Therapy A preliminary follow-up study with former clients Hans Ossebaard & Nicole Maalste Bulletin of the Multidisciplinary Association for Psychedelic Studies, MAPS : 1999, Vol 9, N° 2, pp. 3-9 This study was made possible in part by a grant to MAPS from the Promind Foundation The present pilot study is a preliminary investigation among former clients who participated in therapy supervised by Bastiaans and his collaborators (see MAPS Bulletin, VIII (2), p. 3; 1998) and conducted with the help of hallucinogenic drugs. This follow-up study aims to systematically establish the subjective judgements of clients, to work out a profile that [...]
Lire la suiteThe abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act Matthew W. Johnson, Roland R. Griffiths, Peter S. Hendricks, Jack E. Henningfiel Neuropharmacology, 2018, 142, 143-166. https://doi.org/10.1016/j.neuropharm.2018.05.012 a b s t r a c t This review assesses the abuse potential of medically-administered psilocybin, following the structure of the 8 factors of the US Controlled Substances Act (CSA). Research suggests the potential safety and efficacy of psilocybin in treating cancer-related psychiatric distress and substance use disorders, setting the occasion for this review. A more extensive assessment of abuse potential according to an 8-factor analysis would eventually be required to [...]
Lire la suiteMicrodosing psychedelics: More questions than answers? An overview and suggestions for future research Kim P.C. Kuypers, Livia Ng, David Erritzoe, Gitte M. Knudsen, Charles D. Nichols, David E. Nichols, Luca Pani, Anaïs Soula and David Nutt Journal of Psychopharmacology, 2019, 1-10. Doi: 10.1177/0269881119857204 Abstract Background : In the past few years, the issue of ‘microdosing’ psychedelics has been openly discussed in the public arena where claims have been made about their positive effect on mood state and cognitive processes such as concentration. However, there are very few scientific studies that have specifically addressed this issue, and there is no agreed scientific consensus on what microdosing [...]
Lire la suitePositive psychology in the investigation of psychedelics and entactogens : A critical review Henrik Jungaberle, Sascha Thal, Andrea Zeuch, Ansgar Rougemont-Bücking, Maximilian von Heyden, Helena Aicher, Milan Scheidegger Neuropharmacology, 2018 PII: S0028-3908(18)30336-8 DOI: 10.1016/j.neuropharm.2018.06.034 Rationale : We reviewed the concepts and empirical findings in studies with psychedelics and entactogens related to positive psychology – the study of healthy human functioning, well-being and eudaemonia. It is an unresolved question how beneficial effects of psychedelics and entactogens are related to the potential risks of these substances – particularly in non-clinical settings. Methods : We searched in PubMed, PsychINFO and the Cochrane Library for controlled clinical and epidemiological studies [...]
Lire la suiteHuman hallucinogen research : Guidelines for safety. Matthew W. Johnson, William A. Richards, Roland R. Griffiths Journal of Psychopharmacology, 2008, 22, 603–620. doi : 10.1177/0269881108093587 Abstract There has recently been a renewal of human research with classical hallucinogens (psychedelics). This paper first briefly discusses the unique history of human hallucinogen research, and then reviews the risks of hallucinogen administration and safeguards for minimizing these risks. Although hallucinogens are relatively safe physiologically and are not considered drugs of dependence, their administration involves unique psychological risks. The most likely risk is overwhelming distress during drug action ('bad trip'), which could lead to potentially dangerous behaviour such as [...]
Lire la suiteThe tripping point : The potential role of psychedelic-assisted therapy in the response to the opioid crisis Elena Argento, Kenneth W. Tupper, M. Eugenia Socias International Journal of Drug Policy, 2019, 66, 80–81 https://doi.org/10.1016/j.drugpo.2018.11.006 0955-3959/ © 2018 Elsevier B.V. All rights reserved A B S T R A C T The increasing contamination of the drug supply with illicitly manufactured fentanyl and related analogs in North America has resulted in the most severe drug-overdose crisis in history. Available pharmaco-therapy options for the treatment of opioid use disorder have had limited success in curbing the current crisis, and a growing body of evidence highlights the need for [...]
Lire la suite